13-valent pneumococcal conjugate vaccine
Trials 41
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01531322 | Oct 2011 → Jan 2012 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06703203 | Jul → Aug 2025 | — | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Completed | No outcome recorded |
| Phase 1/2 | NCT00205803 | Sep 2004 → May 2007 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 24 trials · 1 missed | ||||||
| Phase 2 | NCT02482636 | Aug 2015 → Nov 2017 | infectious disease | University of Oxford | Completed | No outcome recorded |
| Phase 2 | NCT00824850 | Jan → Sep 2010 | — | Pfizer | Completed | Missed primary |
| Phase 2 | NCT00689351 | Jun 2008 → Dec 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 2 | NCT00269672 | Sep 2005 → Feb 2007 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 330 trials · 4 met primary | ||||||
| Phase 3 | NCT03571607 | Jul → Nov 2018 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01646398 | Jun → Oct 2012 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01200368 | Sep 2010 → Nov 2011 | — | Pfizer | Completed | Met primary |
| Phase 3 | NCT01026038 | Apr → Nov 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00963235 | Nov 2009 → May 2012 | HIV infectious disease, pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00853749 | May → Dec 2009 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00743652 | Jan 2009 → Sep 2010 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00761631 | Dec 2008 → Jul 2010 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00708682 | Jul 2008 → May 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00688870 | Jun 2008 → Jan 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00500266 | May 2008 → Apr 2009 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00676091 | Apr 2008 → Sep 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00508742 | Dec 2007 → Aug 2011 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00574548 | Nov 2007 → Feb 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
| Phase 3 | NCT00546572 | Nov 2007 → Jul 2010 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | Met primary |
| Phase 3 | NCT00500357 | Nov 2007 → Jan 2010 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00521586 | Sep 2007 → Dec 2013 | influenza | Pfizer | Completed | Met primary |
| Phase 3 | NCT00492557 | Sep 2007 → Feb 2008 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00474539 | Jul 2007 → Mar 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00452452 | Jul 2007 → Mar 2008 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00452790 | Jun 2007 → Oct 2009 | pneumococcal infection | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00475033 | Jun 2007 → May 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00464945 | Jun 2007 → Sep 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00444457 | May 2007 → Jun 2009 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00427895 | Feb 2007 → Aug 2011 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00366678 | Oct 2006 → Nov 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00368966 | Oct 2006 → Jul 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00384059 | Oct 2006 → Oct 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00366899 | Oct 2006 → Jul 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00366340 | Oct 2006 → Aug 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 44 trials · 1 missed | ||||||
| Phase 4 | NCT05329259 | Oct → Nov 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02124161 | Sep 2014 → May 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT02034877 | Aug 2014 → Jul 2015 | — | Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT01392378 | Aug 2011 → Jan 2013 | — | Pfizer | Completed | Missed primary |
| Comparator or background therapy14 trials | ||||||
| Phase 0 | NCT02558751 Comparator | Jul 2013 → Jun 2015 | pneumococcal infection | University of Toledo Health Science Campus | Completed | No outcome recorded |
| Phase 1 | NCT06970756 Comparator | May → Nov 2025 overdue | pneumococcal infection | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Not yet recruiting | No outcome recorded |
| Phase 2 | NCT05084508 Background | Feb 2022 → Feb 2024 | chickenpox | GlaxoSmithKline | Completed | No outcome recorded |
| Phase 3 | NCT05512819 Comparator | Sep 2022 → Sep 2025 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT05408429 Comparator | Jun 2022 → Jun 2023 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04530838 Comparator | Sep 2020 → Apr 2022 | pneumococcal infection | Pfizer | Completed | Mixed |
| Phase 3 | NCT04546425 Comparator | Sep 2020 → Apr 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04357522 Comparator | Jul 2020 → Mar 2026 | streptococcal pneumonia | Beijing Zhifei Lvzhu Biopharmaceutical Co., Ltd | Unknown | No outcome recorded |
| Phase 3 | NCT04379713 Comparator | May 2020 → Aug 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT04382326 Comparator | May 2020 → Sep 2022 | pneumococcal infection | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT01964716 Comparator | Jan → Sep 2014 | — | Pfizer | Completed | No outcome recorded |
| Phase 3 | NCT00366548 Comparator | Nov 2006 → Jun 2008 | — | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase 4 | NCT03762824 Comparator | Jun 2016 → Sep 2018 | Sjogren syndrome, rheumatoid arthritis, spondyloarthropathy, systemic lupus erythematosus +1 | Region Skane | Completed | No outcome recorded |
| Phase 4 | NCT01193335 Comparator | Oct 2010 → Jan 2014 | — | Pfizer | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2016-07-12 | Pfizer | Pfizer Receives FDA Approval for Prevnar 13® in Adults Age 18 Through 49 pfizer.com ↗ |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 77 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | 13-valent pneumococcal conjugate vaccine | ClinicalTrials.gov intervention name — accepted as the source's own label NCT04546425 ↗ |
| Known as | 13-valent PCV | “A recently licensed 13-valent PCV (PCV13) was developed to provide additional coverage globally.” PMID 21983216 ↗ Dec 2011 |
| Known as | 13vPnC | “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to 7-valent pneumococcal...” NCT00366340 ↗18“The objective of this study is to compare the immune response of 2 different 13-valent pneumococcal conjugate (13vPnC) formulations with and without AlPO4 to select a...” NCT00269672 ↗ “This study will further evaluate the safety, tolerability, and immunogenicity of 13-valent pneumococcal conjugate vaccine (13vPnC) when administered to subjects who have...” NCT00500357 ↗ “Single 0.5 milliliter (mL) 13-valent pneumococcal conjugate vaccine (13vPnC) and a single 0.5 mL trivalent inactivated influenza vaccine (TIV), administered intramuscularly...” NCT00492557 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00474539 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366899 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00368966 ↗ “The purpose of this study is to assess the safety, tolerability and immunogenicity of a 13-valent pneumococcal conjugate (13vPnC) vaccine compared to Prevenar (7vPnC), when...” NCT00366678 ↗ “Participants will receive either the study vaccine (20vPnC) or a licensed vaccine (13vPnC) as a 4-dose schedule as a shot in the muscle.” NCT05512819 ↗ “a 13-valent Pneumococcal conjugate vaccine (13vPnC)” NCT00452452 ↗ “13-valent pneumococcal conjugate (13vPnC) vaccine” NCT00384059 ↗ |
| Known as | PCV13 | “This open-label randomized controlled trial in infants compared safety, tolerability, and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) formulated with...” PMID 28479175 ↗ May 201722“This phase 3, randomized, partially double-blind study investigated the safety, tolerability, and immunogenicity of 20-valent pneumococcal conjugate vaccine (PCV20) in healthy...” PMID 40081152 ↗ Mar 2025 “13-valent pneumococcal conjugate vaccine (PCV13) includes polysaccharide conjugates from six pneumococcal serotypes in addition to those in the licensed 7-valent vaccine,...” PMID 21335032 ↗ Feb 2011 “The objective of this study was to provide safety data for single-dose 13-valent pneumococcal conjugate vaccine (PCV13) in Chinese subjects, needed to begin a phase III safety...” PMID 26668712 ↗ Dec 2015 “This study assessed whether paracetamol or ibuprofen prophylaxis interfere with immune responses to the 13-valent pneumococcal conjugate vaccine (PCV13) given concomitantly...” PMID 28262330 ↗ Mar 2017 “This phase 3, double-blind study randomized healthy Japanese infants to receive 4 doses (3 infant doses, 1 toddler dose) of PCV20 by subcutaneous (SC) or intramuscular (IM)...” PMID 38242195 ↗ Jan 2024 “The safety and immunogenicity of PCV7 were compared with those of 13-valent PCV (PCV13), which contains saccharides from serotypes 1, 3, 4, 5, 6A, 6B, 7F, 9V, 14, 18C, 19A,...” PMID 20435707 ↗ May 2010 “This randomized open-label trial was designed to provide preliminary immunogenicity and safety data to support development of the pediatric 13-valent pneumococcal conjugate...” PMID 24576885 ↗ Feb 2014 “Two randomized trials of 13-valent pneumococcal conjugate vaccine (PCV13) relative to PCV7 evaluated the immune responses of coadministered antigens comprising Infanrix(®)...” PMID 21704105 ↗ Jun 2011 “The 13-valent pneumococcal conjugate vaccine (PCV13) is approved and World Health Organization-prequalified for administration in a 2+1 schedule when used as part of routine...” PMID 23965217 ↗ Aug 2013 “This open-label, single-arm, phase 3 study evaluated safety and immunogenicity of the 13-valent pneumococcal conjugate vaccine (PCV13) in pneumococcal vaccine-naive Japanese individuals” PMID 34563397 ↗ Sep 2021 |
| Known as | Prevnar 13 | “a 13-valent pneumococcal conjugate vaccine (Prevnar 13)” NCT05084508 ↗ |
| Modality | Vaccine | “13-valent pneumococcal conjugate vaccine” NCT00269672 ↗ |
| Route | Intramuscular | “0.5 mL of study vaccine administered IM at 2, 4, 6, and 12 months of age.” NCT00444457 ↗ |